Ann Marie Egloff, PhD

Research Associate Professor, Molecular & Cell Biology

Ann Egloff
(617) 414-1014
650 Albany St Evans Biomed Research Ctr

Other Positions

  • Research Associate Professor, Otolaryngology-Head & Neck Surgery, Boston University School of Medicine

Education

  • Johns Hopkins University, PhD
  • University of Pittsburgh, MPH

Publications

  • Published on 4/9/2017

    Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncol. 2017 Jun; 69:38-45. PMID: 28559019.

    Read at: PubMed
  • Published on 4/26/2016

    Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget. 2016 Apr 26; 7(17):23300-11. PMID: 27004400.

    Read at: PubMed
  • Published on 12/18/2015

    Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res. 2016 Mar; 14(3):278-86. PMID: 26685214.

    Read at: PubMed
  • Published on 5/1/2015

    Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44. PMID: 26181029.

    Read at: PubMed
  • Published on 2/6/2015

    Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. PLoS One. 2015; 10(2):e0117781. PMID: 25658924.

    Read at: PubMed
  • Published on 12/12/2014

    Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM. Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. Cancer Lett. 2015 Feb 28; 357(2):549-56. PMID: 25511740.

    Read at: PubMed
  • Published on 8/8/2014

    Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res. 2014 Oct 1; 20(19):5041-51. PMID: 25107914.

    Read at: PubMed
  • Published on 8/3/2014

    Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664.

    Read at: PubMed
  • Published on 6/16/2014

    Kagawa S, Natsuizaka M, Whelan KA, Facompre N, Naganuma S, Ohashi S, Kinugasa H, Egloff AM, Basu D, Gimotty PA, Klein-Szanto AJ, Bass AJ, Wong KK, Diehl JA, Rustgi AK, Nakagawa H. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene. 2015 Apr 30; 34(18):2347-59. PMID: 24931169.

    Read at: PubMed
  • Published on 6/10/2014

    Choby GW, Albergotti WG, Byrd JK, Egloff AM, Johnson JT. Factors contributing to recurrence of oral cavity and laryngeal tumors and estimation of tumor age. Laryngoscope. 2014 Oct; 124(10):2297-304. PMID: 24913023.

    Read at: PubMed

View 35 more publications: View full profile at BUMC

View all profiles